Skyhawk's SKY-0515 Secures TGA Provisional Approval Eligibility for Huntington's Treatment

Skyhawk Therapeutics has announced that its oral small molecule therapy, SKY-0515, for Huntington's disease has met Australia's Therapeutic Goods Administration's (TGA) eligibility criteria for registration through the provisional approval pathway. This step could expedite the Australian approval process for this potential disease-modifying treatment, which is highly anticipated due to the lack of such therapies for Huntington's disease.

The ongoing Phase 1C trials for SKY-0515 involve over 115 patients, showing promising results in improving Huntington's disease symptoms. Specifically, the treatment has demonstrated dose-dependent reductions in key disease drivers, mHTT and PMS1, along with favorable central nervous system exposure and tolerability.

Huntington's disease affects hundreds of thousands globally, with over 40,000 symptomatic cases in the U.S. and more than 2,000 in Australia. Currently, there are no approved therapies that slow disease progression. SKY-0515 is pioneering clinical trials from Skyhawk, a company focusing on RNA-targeting small molecule therapies.